Abstract
Coinfection of hepatitis C virus (HCV)-infected patients with HIV or hepatitis B virus (HBV) is common because of shared modes of transmission. Coinfection with HBV or HIV has been shown to accelerate the course of chronic hepatitis C and facilitate progression to cirrhosis and hepatocellular carcinoma. Currently, the combination of pegylated interferon and ribavirin is the best available treatment in HIV/HCV-coinfected patients. The optimal treatment of HCV in persons with HBV coinfection has not been defined but may include pegylated interferon alpha plus ribavirin initially, followed by oral anti-HBV agents, such as lamivudine or adefovir, or both.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
